Post-transplant lymphoproliferative disease
MONDO:0019088Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)
Also known as: PTLD, post-transplant lymphoproliferative disorder
31 clinical trials for this condition and its sub-types, 28 tagged with Post-transplant lymphoproliferative disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New vaccine aims to stop Virus-Linked cancers in organ transplant patients
Vaccine Recruiting nowThis early-stage trial tests a vaccine called OSU-2131, designed to help the immune system fight Epstein-Barr virus (EBV). EBV can cause cancers in people who have weakened immune systems, such as those awaiting organ transplants. The study includes healthy volunteers and transpl…
Phase 1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Vaccine
Last updated Jul 04, 2026 00:00 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Donor immune cells take on Virus-Linked cancer after transplant
Disease control Recruiting nowThis phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…
Phase 3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Immune cells take aim at Post-Transplant virus
Disease control Recruiting nowThis early-stage study tests a new treatment using specially grown immune cells (EBV-AST cells) to fight EBV infections in people who have had a stem cell transplant. The trial will enroll 18 adults with persistent EBV in their blood. Researchers will test three different doses t…
Phase 1 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug duo aims to tackle tough lymphoma in immunocompromised patients
Disease control Recruiting nowThis phase II trial tests whether combining epcoritamab (an immunotherapy that directs immune cells to kill lymphoma) with lenalidomide (which boosts the immune system) can shrink tumors in 34 patients whose immunodeficiency-related large B-cell lymphoma has not responded to trea…
Phase 2 • Sponsor: Reem Karmali • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Blood test may spare some transplant patients from chemo
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can help doctors choose the right treatment for people with a type of lymphoma that happens after an organ transplant (PTLD). About 30 participants will be split into low-risk and high-risk groups. Low-risk patients will get only the …
Phase 2 • Sponsor: Jennifer Amengual • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug duo aims to tackle Transplant-Related lymphoma
Disease control Recruiting nowThis study tests whether combining two antibody drugs, tafasitamab and rituximab, can effectively treat a type of lymphoma that sometimes occurs after an organ transplant. About 28 adults who have developed this condition will receive the drug combination. The main goal is to see…
Phase 2 • Sponsor: Timothy Voorhees • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cell therapy targets EBV-Linked cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the t…
Phase 1/2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New immune cell therapy takes on virus after transplant
Disease control Recruiting nowThis early-phase study tests a new treatment for Epstein-Barr virus (EBV) that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and destroy virus-infected cells. Up to 18 adult patients who have persistent EBV …
Phase 1/2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC